NSE:PANACEABIO
PANACEA BIOTEC LTD
Healthcare › Pharmaceuticals & Biotechnology
₹376.50
at close · 21 Sept 2026
Latest filings
- Reminder to physical shareholders for PAN and KYC updation · Compliance
- Panacea Biotec publishes 42nd AGM notice and e-voting details in newspapers · Compliance
- Book closure Sept 25 to Sept 29, 2026 for 42nd AGM · Board & Shareholder Meetings
- AGM Notice and Annual Report FY25-26 Weblink Shared with Shareholders · Compliance
- Notice of 42nd Annual General Meeting on September 29, 2026 · Board & Shareholder Meetings
- Shares demat update for August 2026 · Compliance
- Newspaper notice published for 42nd AGM on Sep 29, 2026 · Compliance
- Q1 FY27 Results: Revenue Up About 20% YoY, Turns Profitable; Going Concern Note · Results
- Newspaper notice on special window for physical share transfer and dematerialisation · Compliance
- Board Meeting on Aug 13 2026 to Approve Q1 FY27 Results · Results
- No shares dematerialised in July 2026, total demat count unchanged at 6.11 crore · Compliance
- Panacea Biotec gets UNICEF polio vaccine supply order worth USD 8.2 million for CY2028 · Business Updates
- Subsidiary gets GST show cause notice for Rs 4.06 crore ITC dispute · Regulatory & Legal
- Filed appeal against fourth industrial tribunal award; High Court grants interim relief · Regulatory & Legal
- Promoter gifts 2 lakh Panacea Biotec shares to own HUF · Ownership Changes
- Panacea Biotec reports no share dematerialization in June 2026 · Compliance
- Compliance certificate for share dematerialization, Q1 FY27 · Compliance
- Panacea Biotec files appeals against tribunal awards on labour disputes · Regulatory & Legal
- RTA compliance certificate filed for Q1 FY27 under SEBI Reg 74(5) · Compliance
- No shares dematerialized during June 2026 · Compliance
- Trading window closed from July 1 ahead of Q1 results · Compliance
- Trading window closed from July 1 for Q1 results announcement · Compliance
- Promoter Dr. Rajesh Jain gifts 2 lakh shares to HUF (inter-se transfer) · Ownership Changes
- Newspaper notice on special window for physical share dematerialization · Compliance
- Newspaper notice on special window for physical share transfer/dematerialisation · Compliance
- Panacea Biotec Limited has informed the Exchange regarding a press release dated Jun 08, 2026, titled "Launch of the DENSTAR project: advancing the licensure of a tetravalent liveattenuateddengue vaccine (DengiAll®) in sub-Saharan Africa and to facilitate its global access". · Business Updates
- Rajesh Jain has Submitted to the Exchange a copy of Disclosure under Regulation 10 (5) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. · Ownership Changes
- Panacea Biotec Limited has informed the Exchange regarding 'Details of Shares dematerialized during May 2026 under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018'. · Compliance
- Panacea Biotec Limited has informed the Exchange about Copy of Newspaper Publication · Compliance
- Please find attached results · Management Changes
- We would like to inform you that the Board of Directors has at its meeting held today i.e. 30.05.2026 approved the appointment of Mr. Rajinder Singh Manku as an additional director in the .... · Management Changes
- Panacea Biotec Limited has informed the Exchange regarding Change in Director(s) of the company. · Results
- We would like to inform you that the Board of Directors has at its meeting held today, i.e. Saturday, May 30, 2026, inter-alia, considered and approved: 1. the Standalone and Consolidated .... · Results
- Panacea Biotec Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026. · Results
- We would like to inform you that the Board of Directors of the Company''s material wholly owned subsidiary, Panacea Biotec Pharma Ltd., has in its meeting held today i.e. 29.05.2026 , inter-alia, .... · Management Changes
- Please find enclosed Secretarial Compliance Report duly issued by R&D Company Secretaries, Practicing Company Secretaries for the financial year ended March 31, 2026. · Compliance
- Panacea Biotec Limited has informed the Exchange about change in directors in the Company's material wholly owned subsidiary, Panacea Biotec Pharma Limited · Management Changes
- The Board Meeting to be held on 29/05/2026 has been revised to 30/05/2026 The Board Meeting to be held on 29/05/2026 has been revised to 30/05/2026 · Board & Shareholder Meetings
- Panacea Biotec Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2026 ,inter alia, to consider and approve Standalone and Consolidated .... · Results
- Please find enclosed herewith the details of shares dematerialised during April 2026 under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 · Compliance
- Panacea Biotec Limited has informed the Exchange regarding 'Details of Shares dematerialized during April 2026 under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018'. · Compliance
- Fire at Panacea Biotec subsidiary's oncology lab in Baddi; ops disrupted 5-7 days · Capex & Operations
- ITAT allows Panacea Biotec appeal; ₹9.16 Cr tax demand cancelled · Regulatory & Legal
- Panacea Biotec Limited has informed the Exchange about Copy of Newspaper Publication regarding notice intimating the investors about the opening of a Special Window for Transfer and Dematerialization of physical shares, in accordance with SEBI Circular No. HO/38/13/11(2)2026-MIRSD-POD/I/3750/2026 dated January 30, 2026, published on April 15, 2026. · Compliance
- Panacea Biotec Limited has informed the Exchange about Bagging/Receiving of orders/contracts from Central Medical Services Society, Ministry of Health and Family Welfare, Government of India ( CMSS ) for supply of Diphtheria and Tetanus Vaccine (Absorbed) for Adults and Adolescents IP ( Td Vaccine ) in several tranches to CMSS for the value aggregating to INR 20.79 Crore. · Business Updates
- Tribunal rules against Panacea Biotec in workmen dispute; to appeal · Regulatory & Legal
- Panacea Biotec Limited has informed the Exchange regarding 'Details of Shares dematerialized during March 2026 under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018'. · Compliance
- Panacea Biotec Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018 · Compliance
- Panacea Biotec Limited has informed the Exchange about the receipt of rectified Assessment Order dated 06.04.2026 from the Deputy Commissioner of Income Tax. Under this order, the errors have been corrected, and the Company's tax liability for AY 2016-17 has been determined as Nil. · Regulatory & Legal
- Panacea Biotec Limited has informed the Exchange about the receipt of rectified Assessment Order dated 06.04.2026 from the Deputy Commissioner of Income Tax. Under this order, the errors have been corrected, and the Company's tax liability for AY 2015-16 has been determined as Nil. · Regulatory & Legal
Snapshot
What the business is, and whether it's a good one at a fair price.
A Pharmaceuticals & Biotechnology company listed on NSE and BSE, reporting revenue of ₹673 Cr over the trailing twelve months.
Market Cap
₹2,308 Cr
P / E (TTM)
—
EV / EBITDA
79.6×
Div Yield
—
Growth
0.5%▲
Revenue 5y CAGR
PAT — · EBITDA -18.2%
Quality
0.5%·
ROCE (5y median)
ROE -0.9% · margin 5.0%
Leverage
0.03·
Debt / Equity · low
Net debt ₹-34 Cr
Revenue FY21→FY26
1.0×▲
Margin +22.5 pts
₹625 Cr → ₹640 Cr
Cash conversion
-0.53×▼
Operating cash ÷ profit · 5 yrs
₹-543 Cr on ₹1,027 Cr
Moves on a normal day
1.73%·
Median daily move
Last 268 sessions · filing days run larger
Where it sits among 185 Pharmaceuticals peersBar = share of peers beaten · tick = industry median · latest reported figures
P/B#74/164
ROCE#155/183
ROE#149/171
Debt / Equity#61/171
EBITDA margin#137/165
Revenue growth#70/161
Profit growth#129/158
Scorecard
Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice
Strengths
Debt at 0.03× equity
lower than 65% of its 171 Pharmaceuticals peers
Concerns
Slow revenue growth — 1% a year over 5 years
Returns on capital 0.5% (5-year median)
#155 of 183 in Pharmaceuticals on the latest reported figures · down from 5.4% in FY21
Over 5 years it reported ₹1,027 Cr of profit and ₹-543 Cr of operating cash — -0.53×
Less than 60p of every ₹1 of profit arrived as cash
Charts
How has the market priced it — with filings on the timeline?
PANACEABIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Peers
How does it stack up on valuation, returns and growth?
Loading peers…
Financials
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Ownership
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Common questions
Answered from PANACEA BIOTEC LTD's filed financials and exchange disclosures
What does PANACEA BIOTEC LTD do?
PANACEA BIOTEC LTD is a Pharmaceuticals & Biotechnology company listed on NSE and BSE, trading under the symbol PANACEABIO.
Is PANACEA BIOTEC LTD profitable?
No. Over the trailing twelve months PANACEA BIOTEC LTD reported a net loss of ₹9 Cr on revenue of ₹673 Cr.
Does PANACEA BIOTEC LTD pay a dividend?
Not in the latest reported year — PANACEA BIOTEC LTD's dividend payout for FY26 was nil.
Is PANACEA BIOTEC LTD debt-free?
Effectively yes. It holds ₹34 Cr more cash than debt. Debt stands at 0.03× equity.
How much does the PANACEA BIOTEC LTD share price move in a day?
On a typical session PANACEA BIOTEC LTD moves 1.73% — that is the median absolute close-to-close move across its last 268 trading days. Announcement days are routinely larger.
Where can I track PANACEA BIOTEC LTD's announcements?
Every NSE and BSE filing by PANACEA BIOTEC LTD appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.